Brain natriuretic peptide

AL amyloidosis

Natriuretic peptide

Cardiology

Immunology

Heart failure

Internal medicine

Medicine

Amyloidosis

Immunoglobulin light chain

Antibody

Cardiac amyloidosis

British Journal of Haematology

Summary Severity of cardiac involvement remains the leading determinant of survival in light chain (AL) amyloidosis. Until recently, cardiac response after treatment relied on reduction of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP). In this study, 94 patients with AL amyloidosis (baseline BNP ≥150 pg/ml) had BNP measured at 6 months following treatment. Median overall survival was not reached for cardiac response (≥50 pg/ml and ≥ 30% decrease in BNP), 9·2 years for cardiac stability (&lt;50 pg/ml and &lt;30% change in BNP) and 2·8 years for cardiac progression (≥50 pg/ml or ≥30% increase in BNP) (log‐rank P &lt; 0·001). Cardiac response and progression, as measured by BNP values, are significantly associated with survival in AL amyloidosis.

Establishment of brain natriuretic peptide ‐ based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis